BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38302471)

  • 21. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
    Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
    J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
    Tabernero J; Cervantes A; Rivera F; Martinelli E; Rojo F; von Heydebreck A; Macarulla T; Rodriguez-Braun E; Eugenia Vega-Villegas M; Senger S; Ramos FJ; Roselló S; Celik I; Stroh C; Baselga J; Ciardiello F
    J Clin Oncol; 2010 Mar; 28(7):1181-9. PubMed ID: 20100964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potential colorectal cancer serum biomarkers through quantitative proteomics on the colonic tissue interstitial fluids from the AOM-DSS mouse model.
    Wang Y; Shan Q; Hou G; Zhang J; Bai J; Lv X; Xie Y; Zhu H; Su S; Li Y; Zi J; Lin L; Han W; Zhao X; Wang H; Xu N; Wu L; Lou X; Liu S
    J Proteomics; 2016 Jan; 132():31-40. PubMed ID: 26581642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer.
    Kim SY; Kim K; Cho SH; Chun SM; Tak E; Hong YS; Kim JE; Kim TW
    Cancer Genet; 2021 Nov; 258-259():27-36. PubMed ID: 34315006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.
    El Hallal R; Lyu N; Wang Y
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
    Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
    Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
    Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
    Kim SA; Park H; Kim KJ; Kim JW; Sung JH; Nam M; Lee JH; Jung EH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Lee KW
    Sci Rep; 2021 Dec; 11(1):23803. PubMed ID: 34893673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage mannose receptor 1 and S100A9 were identified as serum diagnostic biomarkers for colorectal cancer through a label-free quantitative proteomic analysis.
    Fan NJ; Chen HM; Song W; Zhang ZY; Zhang MD; Feng LY; Gao CF
    Cancer Biomark; 2016; 16(2):235-43. PubMed ID: 26682511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
    Bhardwaj M; Weigl K; Tikk K; Holland-Letz T; Schrotz-King P; Borchers CH; Brenner H
    Eur J Cancer; 2020 Mar; 127():30-40. PubMed ID: 31972396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.
    Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y
    Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
    Jing C; Wang T; Ma R; Cao H; Wang Z; Liu S; Chen D; Zhang J; Wu Y; Zhang Y; Wu J; Feng J
    Mol Carcinog; 2020 May; 59(5):478-491. PubMed ID: 32141150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.